MIRA INFORM
REPORT
|
Report Date : |
16.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
INTER-VETPHARMA LTD. |
|
|
|
|
Registered Office : |
c/o Cheuk Ying Enterprise Management Ltd., Room 1609D2, 16/F., Nan Fung Tower, 173 Des Voeux Road Central |
|
|
|
|
Country : |
Hong Kong |
|
|
|
|
Date of Incorporation : |
13.08.2009 |
|
|
|
|
Com. Reg. No.: |
51010931 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Importer, Exporter and Wholesaler of all kinds of pharmaceuticals for animals, etc. |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Small Company |
|
Payment
Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
Hong Kong |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name
INTER-VETPHARMA LTD.
Company ADDRESS
c/o Cheuk Ying Enterprise Management Ltd.
Room 1609D2, 16/F., Nan Fung Tower, 173 Des Voeux Road Central, Hong Kong.
PHONE: 2152 7377
FAX: 3019 7642
E-MAIL: sales@inter-vetpharma.com
MANAGEMENT
Managing Director: Mr. Wang Lin
SUMMARY
Incorporated on: 13th August, 2009.
Organization: Private Limited Company.
Capital: Nominal: HK$10,000.00
Issued: HK$10,000.00
Business Category: Pharmaceutical Trader.
Employees: Nil.
Main Dealing Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Banking Relation: Satisfactory.
Company ADDRESS
Registered Head
Office:-
c/o Cheuk Ying Enterprise Management Ltd.
Room 1609D2, 16/F., Nan Fung Tower, 173 Des Voeux Road Central, Hong Kong.
Main Associated
Company:-
China Inter-Vetpharma Ltd.
East Coast 13-17-4, Jiangbei District, Chongqing, China.
[Tel/Fax: 86-023-6332 7661]
BUSINESS REGISTRATION NUMBER
51010931
COMPANY FILE NUMBER
1362317
MANAGEMENT
Managing Director: Mr. Wang Lin
CAPITAL
Nominal Share Capital: HK$10,000.00 (Divided into 10,000 shares of HK$1.00 each)
Issued Share Capital: HK$10,000.00
SHAREHOLDER
(As per registry dated 13-08-2010)
|
Name |
|
No. of shares |
|
WANG Lin |
|
10,000 ===== |
DIRECTOR
(As per registry dated 13-08-2010)
|
Name (Nationality) |
Address |
|
WANG Lin |
Flat 21-4, Block 2, New City Oasis, Jiangbei District, Chongqing City, China. |
SECRETARY
(As per registry dated 13-08-2010)
|
Name |
Address |
Co.
No. |
|
Cheuk Ying Enterprise Management Ltd. |
Room 1609D2, 16/F., Nan Fung Tower, 173 Des Voeux Road Central, Hong Kong. |
1158874 |
HISTORY
The subject was incorporated on 13th August, 2009 as a private limited liability company under the Hong Kong Companies Ordinance.
Apart from these, neither material change nor amendment has been ever traced and noted.
OPERATIONS
Activities: Importer, Exporter and Wholesaler.
Lines: All kinds of pharmaceuticals for animals, etc.
Employees: Nil.
Commodities Imported: Germany, India, etc.
Markets: China, Japan, other Asian countries, Europe, North America, etc.
Terms/Sales: L/C, T/T, etc.
Terms/Buying: L/C, T/T, D/P, etc.
FINANCIAL INFORMATIOn
Nominal Share Capital: HK$10,000.00 (Divided into 10,000 shares of HK$1.00 each)
Issued Share Capital: HK$10,000.00
Profit or Loss: Too early to offer an opinion.
Condition: Business is under development.
Facilities: Making fairly active use of general banking facilities.
Payment: Met trade commitments as required.
Commercial Morality: Satisfactory.
Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Standing: Small.
GENERAL
Having issued 10,000 ordinary shares of HK$1.00 each, Inter-Vetpharma Ltd. is wholly owned by Mr. Wang Lin who is a China merchant. He is also the only director of the subject. Currently residing in Chongqing City, China, Wang is a China ID holder and does not have the right to reside in Hong Kong permanently.
The subject does not have its own operating office. Its registered office is in a commercial service firm located at Room 1609D2, 16/F., Nan Fung Tower, 173 Des Voeux Road Central, Hong Kong known as Cheuk Ying Enterprise Management Ltd. which is handling its correspondences and documents. This firm is also the corporate secretary of the subject. The subject has no employees in Hong Kong.
To our knowledge, the subject has had an associated company in Chongqing City, China known as China Inter-Vetpharma Ltd. [China Inter-Vetpharma] which is also operated by Wang. China Inter-Vetpharma and its subsidiaries have established a long term technological cooperation with some of the famous pharmaceutical colleges and research institutes in China and abroad. Currently it is specialized in active pharmaceutical ingredients [API], veterinary drugs, agrochemicals, bio-chemicals, intermediates and specialty chemicals. China Inter-Vetpharma is a manufacturer and provider of pharmaceuticals and chemicals in China.
The followings are the main products of China Inter-Vetpharma:-
Amoxycillin Trihydrate compacted/ powder
Amoxycillin sodium sterile
Ampicillin Trihydrate powder
Ampicillin sodium + Sulbactam sodium mixture (2:1) sterile
other antibiotics
Nitroxynil
Tiamulin Hydrogen Fumarate [CAS: 55297-96-6]
Closantel Base [CAS: 57808-65-8]
Closantel Sodium [CAS: 61438-64-0]
Atovaquone [CAS: 95233-18-4]
Buparvaquone [CAS: 88426-32-9]
Ivermectin [CAS: 70288-86-7]
Avermectin (Abamectin) [CAS: 71751-41-2]
Monensin [CAS: 17090-79-8]
Doramectin [CAS: 117704-25-3]
Ceftiofur HCL [CAS: 103980-44-5]
Carprofen [CAS: 53716-49-7]
Colistin Sulphate [CAS: 1264-72-8]
Carbasalate calcium [CAS: 5749-67-7]
Doxycycline hydrochloride [CAS: 10592-13-9]
Lincomycin hydrochloride [CAS: 7179-49-9]
Fipronil [CAS: 120068-37-3]
Flunixin Meglumine [CAS: 42461-84-7]
Imidocarb dipropionate [CAS: 27885-92-3]
Thiamphenicol [CAS: 15318-45-3]
Florfenicol [CAS: 76639-94-6]
Baclofen [CAS: 1134-47-0]
Menbutone [CAS: 3562-99-0]
Butafosfan [CAS: 17316-67-5]
Bambuterol HCl [CAS: 81732-65-2]
Oxytetracycline Base
Oxytetracycline HCL
Tylosin Phosphate
Tylosin Tartrate
Tilmicosin (Phosphate) [CAS: 108050-54-0]
Toltrazuril [CAS: 69004-03-1]
Diclazuril [CAS: 101831-37-2]
Pimobendan [CAS: 74150-27-9]
Praziquantel [CAS: 55268-74-1]
Enrofloxacin HCL (Base)
Norfloxacin HCL (Base)
Ciprofloxacin HCL
Rafoxanide [CAS: 22662-39-1]
Roxarsone [CAS: 121-19-7]
Albendazole [CAS: 54965-21-8]
Fenbendazole [CAS: 43210-67-9]
Flubendazole [CAS: 88495-63-0]
Mebendazole [CAS: 31431-39-7]
Oxyclozanide [CAS: 2277-92-1]
Oxfendazole [CAS: 53716-50-0]
Oxibendazole [CAS: 20559-55-1]
Parbendazole [CAS: 14255-87-9]
Most of the products are marketed in China while small quantities are exported to foreign markets.
It is likely that China Inter-Vetpharma deals with foreign parties under the name of the subject and let foreign firms correspond with the subject’s registered address in Hong Kong. China Inter-Vetpharma also exports commodities to foreign markets under the name of the subject and its registered address in Hong Kong.
The subject’s business in Hong Kong is not very active.
Since the subject does not have its own operating office and has no employees in Hong Kong, consider it good for business engagements on secured basis.
COURT CASES: None per our.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.91 |
|
UK Pound |
1 |
Rs.73.06 |
|
Euro |
1 |
Rs.64.03 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.